You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 114 No. 10, October 1996 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL SCIENCES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (7)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Uveitis Associated With Topical β-Blockers

Roy W. Beck, MD, PhD; Pamela Moke, MSPH; R. Clifford Blair, PhD; Richard Nissenbaum, RPh

Arch Ophthalmol. 1996;114(10):1181-1182.


Abstract

Objective
To assess the incidence of uveitis associated with topical β-blockers.

Design
Retrospective cohort study.

Setting
A computerized database of a health maintenance organization was used to identify patients who were prescribed metipranolol or other β-blockers.

Patients
Two groups: 1928 patients using 0.3% metipranolol and 3903 patients using other β-blockers.

Main Outcome Measure
Cases of uveitis were identified by noting a prescription of a topical corticosteroid and then conducting a chart review.

Results
No cases of uveitis were identified among the 5831 patients. The upper limits of the 95% confidence intervals for the incidence of uveitis in cohorts of this size are 1.87 cases per 1000 person-years of exposure for metipranolol and 1.38 for other β-blockers.

Conclusion
Drug-induced uveitis from metipranolol or other β-blocker administration is a rare event, even if a causal relationship exists.



Author Affiliations

From the Jaeb Center for Health Research and the Department of Epidemiology, University of South Florida College of Public Health, Tampa (Drs Beck and Blair and Ms Moke) and the Humana Health Care Plan of Tampa Bay (Mr Nissenbaum). This study was conducted by the Jaeb Center under a contract with Bausch & Lomb, Pharmaceuticals, Rochester, NY. Dr Beck and Ms Moke are employed by the Jaeb Center and Dr Blair serves as a paid consultant to the center. The Humana Health Care Plan (Mr Nissenbaum) was compensated by the Jaeb Center for providing data.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Incidence of ocular side effects of topical beta blockers in the Netherlands
van Beek et al.
Br J Ophthalmol 2000;84:856-859.
ABSTRACT | FULL TEXT  

Iritis and Hypotony After Treatment With Intravenous Cidofovir for Cytomegalovirus Retinitis
Davis et al.
Arch Ophthalmol 1997;115:733-737.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.